


LIST OF CLAIMS


1. (Currently Amended) A compound represented by the following formula (I), a pharmacologically acceptable salt thereof or hydrates thereof:



wherein A represents oxygen; R¹ represents a phenyl having an N,N-di-lower alkylaminoalkoxy group or morpholinyl-lower alkoxy group, pyridyl group or a pyridyl group having a halogen atom, hydroxy group, a lower alkyl group or a lower alkoxy group an optionally substituted aryl group, an optionally substituted heteroaryl group that is formed from one or two 5-6 membered rings that may contain from 1 to 4 heteroatoms, an optionally substituted aralkyl group, an optionally substituted heteroaryl alkyl group, an optionally substituted aryl alkenyl group, an optionally substituted heteroaryl alkenyl group, an optionally substituted piperidyl group, an optionally substituted piperazinyl group, a morpholinyl group, an optionally substituted lower C₃₋₈ cycloalkyl group, a tetrahydrafuranyl group, a tetrahydropyranyl group, an adamantyl group, an optionally substituted amino group or an optionally substituted amide group that is CO-N(R_a)R_b, wherein


~~R_a and R_b are hydrogen or C₁₋₆ alkyl groups; R² represents a phenyl, a phenyl having a halogen atom, a pyridyl group or a pyridyl having a nitril group an optionally substituted aryl group, a 1-9 membered heteroarylalkyl having 1-4, an optionally substituted heteroaryl group that is formed from one or two 5-6 membered rings that may contain from 1 to 4 heteroatoms, an optionally substituted aryl alkenyl group, an optionally substituted heteroaryl alkenyl group, an optionally substituted piperidyl group, an optionally substituted piperazinyl group, a morpholinyl group, an optionally substituted lower C₃₋₈ cycloalkyl group, a tetrahydrefuranyl group, a tetrahydropyranyl group, an adamantyl group, an optionally substituted amino group or an optionally substituted amide group that is CO N(R_a)R_b, wherein R_a and R_b are hydrogen and C₁₋₆ allyl group; and R⁴ and R⁵ are the same as or different from each other and each represents a hydrogen atom, hydroxyl group, nitrile group, nitro group, a lower alkyl group, an aryl group or a heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4 heteroatoms,~~

~~provided that the compounds represented by the following formula (II):~~



(wherein R¹¹ and R¹² are the same as or different from each other and each represents hydrogen atom, fluorine, chlorine, bromine, iodine, a C₁-C₂ fluorealkyl group, a C₁-C₂ chlorealkyl group, a C₁-C₂ bromoalkyl group, a C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl group, a C₇-C₉ aralkyl group, phenyl group, a C₁-C₆ alkoxy group, a C₁-C₆ alkylthio group, a C₁-C₆ alkylsulfinyl group, a C₇-C₉ aralkoxy group, phenoxy group, phenylthio group, phenylsulfonyl group, an alkali metal carboxylate C₂-C₅ alkoxycarbonyl group or a group represented by the formula N(R¹⁵)R¹⁶ (wherein R¹⁵ and R¹⁶ are the same as or different from each other and each represents hydrogen atom or a C₁-C₂ alkyl group); and R¹³ and R¹⁴ are the same as or different from each other and each represents a C₁-C₄ alkylsulfonyl group, nitro group, a group represented by the formula OCH_nX_{3-n} (wherein X represents fluorine, chlorine, bromine or iodine; and n is an integer of 1 to 3) or the same groups as defined above for R¹¹ and R¹²) are excluded.

13. (Currently Amended) A pharmaceutical composition comprising a pharmacologically acceptable amount of the compound represented by the following formula (I), a pharmaceutically acceptable salt thereof or hydrates thereof, and pharmacologically acceptable carriers:



wherein A represents oxygen, sulfur or a group represented by the formula $\rightarrow\text{NR}^3$ (wherein R^3 represents hydrogen atom or a lower alkyl group); R^1 is a phenyl having an N, N-di-lower alkylaminoalkoxy group or morpholinyl-lower alkoxy group, pyridyl group or a pyridyl group having a halogen atom, hydroxy group, a lower alkyl group or a lower alkoxy group; and R^2 is a phenyl, a phenyl having a halogen atom, a pyridyl group or a pyridyl having nitril group; are the same as or different from each other and each represents an optionally substituted aryl group, an optionally substituted heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4 heteroatoms, an optionally substituted aralkyl group, an optionally substituted heteroaryl alkyl group, an optionally substituted aryl alkenyl

group, an optionally substituted heteroaryl alkenyl group, an optionally substituted piperidyl group, an optionally substituted piperazinyl group, a morpholinyl group, an optionally substituted lower C₃-cycloalkyl group, a tetrahydrafuranyl group, a tetrahydropyranyl group, an adamantyl group, an optionally substituted amino group or an optionally substituted amide group that is CO N(R_a)R_b, wherein R_a and R_b are hydrogen and C₁₋₆ alkyl group, and R⁴ and R⁵ are the same as or different from each other and each represents a hydrogen atom, hydroxyl group, halogen atom, nitrile group, nitro group, a lower alkyl group, an aryl group or a heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4

provided that A is an oxygen atom, when R¹ and R² are both phenyl, and

when A is a sulfur atom, R¹ is

an aryl which may have a substituent,

a heteroaryl which may have a substituent that is formed from one or two 5-6 membered rings that may contain 1-4 heteroatoms,

an aralkyl which may have a substituent,

a heteroarylalkyl which may have a substituent

an arylalkenyl which may have a substituent,

a heteroarylalkenyl which may have a substituent,

a piperidyl which may have a substituent,

~~a piperadiny1 which may have a substituent,~~
~~a morpholinyl which may have a substituent,~~
~~a lower C₃₋₆ cycloalkyl which may have a substituent,~~
~~tetrahydrofuranyl,~~
~~adamantyl or~~
~~an optionally substituted amide, that is CO-N(R_a)R_b, wherein R_a and~~
~~R_b are hydrogen and C₁₋₆ alkyl group.~~

14-23. (Canceled)

24. (Currently Amended) A method of treating and ameliorating nerve degeneration diseases, which comprises administering a pharmacologically effective amount of the pharmaceutical preparation according to claim 13 15 or 16 to a patient.

25. (Currently Amended) A method of treating and ameliorating demyelinating nerve diseases, which comprises administering a pharmacologically effective amount of the pharmaceutical preparation according to claim 13 15 or 16 to a patient.

26. (Currently Amended) A method of treating and ameliorating acute nerve degeneration after cerebral ischemia, traumas in the head and spinal injuries, ~~Alzheimer's disease, Parkinson's disease,~~

~~amyotrophic lateral sclerosis, Huntington's chorea, epilepsy, pain, multiple sclerosis, encephalomyelitis, Guillain Barre syndrome, Marchiafava Bignami disease, Devic disease, Balo disease, HIV or HTLV myelopathy or leukoencephalopathy~~, which comprises administering a pharmacologically effective amount of the pharmaceutical preparation according to 13 15 or 16 to a patient.

27-33. Canceled.

34. (NEW) A compound selected from the group consisting of 2-(2-Pyridyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one hydrochloride, 2-(2-pyridyl)-4-(2-bromophenyl)-4H-1,3,4-oxadiazine-5(6H)-one, 2-(2-Pyridyl)-4-(2-fluorophenyl)-4H-1,3,4-oxadiazine-5(6H)-one, 2-Phenyl-4-(2-cyano-3-pyridyl)-4H-1,3,4-oxadiazine-5(6H)-one hydrochloride, 2-[2-(2-Dimethylamino)ethoxyphenyl]-4-(2-bromophenyl)-4H-1,3,4-oxadiazine-5(6H)-one hydrochloride, 2-[2-(2-dimethylaminoethoxy)phenyl]-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one hydrochloride, 2-[2-(2-Dimethylaminoethoxy)phenyl]-4-(2-fluorophenyl)-4H-1,3,4-oxadiazine-5(6H)-one hydrochloride, and 2-{2-[2-(4-Morpholinyl)ethoxyphenyl]}-4-(2-bromophenyl)-4H-1,3,4-oxadiazine-5(6H)-one hydrochloride.